Publication Name	World Journal of Psychiatry
Manuscript ID	65128
Country	Italy

Received	2021-03-01 10:35
Peer-Review Started	2021-03-01 10:35
To Make the First Decision
Return for Revision	2021-07-15 03:00
Revised	2021-07-25 09:51
Second Decision	2021-08-06 03:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-08-06 07:49
Articles in Press	2021-08-06 07:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-11 02:41
Publish the Manuscript Online	2021-09-15 10:23

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Minireviews
Article Title	Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?
Manuscript Source	Invited Manuscript
All Author List	Annalisa Maraone, Lorenzo Tarsitani, Irene Pinucci and Massimo Pasquini
ORCID	Author(s) ORCID Number Annalisa Maraone http://orcid.org/0000-0003-2390-4494 Lorenzo Tarsitani http://orcid.org/0000-0002-1752-966X Irene Pinucci http://orcid.org/0000-0002-2861-7294 Massimo Pasquini http://orcid.org/0000-0003-3959-8137
Funding Agency and Grant Number
Corresponding Author	Massimo Pasquini, MD, PhD, Associate Professor, Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università 30, Rome 00185, Lazio, Italy. massimo.pasquini@uniroma1.it
Key Words	Obsessive-compulsive disorder; Antiglutamatergic agents; Glutammate; Early intervention; Neurophysiopathology; Duration of untreated illness
Core Tip	In pathophysiology of obsessive-compulsive disorder (OCD), dysfunction of the cortico-striatal-thalamo-cortical (CSTC) loop could provoke an imbalance between goal-directed system and habit learning system. Glutamate is the principal neurotransmitter implicated in the CSTC model of OCD. Glutammate dysregulation and neurotoxicity seem to be correlated, thus, an early intervention and a reduction of duration of untreated illness appear central in treatment of OCD, as well as the use of glutamate-modulating drugs that could help to interrupt damage from neurotoxicity.
Publish Date	2021-09-15 10:23
Citation	Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World J Psychiatr 2021; 11(9): 568-580
URL	https://www.wjgnet.com/2220-3206/full/v11/i9/568.htm
DOI	https://dx.doi.org/10.5498/wjp.v11.i9.568

Full Article (PDF)	WJP-11-568.pdf
Full Article (Word)	WJP-11-568.docx
Manuscript File	65128_Auto_Edited-JPY.docx
Answering Reviewers	65128-Answering reviewers.pdf
Audio Core Tip	65128-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	65128-Conflict-of-interest statement.pdf
Copyright License Agreement	65128-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	65128-Language certificate.pdf
Peer-review Report	65128-Peer-review(s).pdf
Scientific Misconduct Check	65128-Bing-Gong SS-2.JPG
Scientific Misconduct Check	65128-Scientific misconduct check.pdf
Scientific Editor Work List	65128-Scientific editor work list.pdf